Aug 14, 2020
Soligenix Announces Recent Accomplishments And Second Quarter 2020 Financial Results
Jun 09, 2020
Soligenix to Present at the MedInvest Infectious Disease and Immunology Investor Conference
May 15, 2020
Soligenix Announces Recent Accomplishments And First Quarter 2020 Financial Results
May 11, 2020
Soligenix Announces Publication of Correlates of Immune Protection for the RiVax® Ricin Toxin Vaccine
May 07, 2020
Soligenix Receives $840,000 in Non-Dilutive Funding Through New Jersey Technology Business Tax Certificate Transfer Program
Apr 16, 2020
Soligenix Announces Exclusive Licensing Agreement for Novel Vaccine Adjuvant from BTG Specialty Pharmaceuticals
Feb 20, 2020
PathSensors, Inc. to sponsor and exhibit at ExperienceFR 2020
Feb 13, 2020
FDA Grants Soligenix "Fast Track" Designation for RiVax® in the Prevention of Ricin Poisoning
Feb 03, 2020
Soligenix Announces Japanese Patent Allowance for Use of Dusquetide in Oral Mucositis
Jan 30, 2020
Soligenix to Present at the 22nd Annual BIO CEO & Investor Conference
Jan 14, 2020
Soligenix - Advancing to Important Inflection Points With Two Pivotal Phase 3 Clinical Trials
Dec 18, 2019
Soligenix to Receive $850,000 in Non-Dilutive Funding Through New Jersey Technology Business Tax Certificate Transfer Program
Dec 12, 2019
Soligenix Initiates Clinical Trial of its Heat Stable Ricin Toxin Vaccine
Nov 18, 2019
Soligenix to Present at the PCG Spotlight Series Conference
Nov 12, 2019
Soligenix Announces Recent Accomplishments And Third Quarter 2019 Financial Results
Nov 06, 2019
Soligenix to Present at the 25th Annual BIO-Europe International Partnering Conference
Oct 24, 2019
Soligenix Receives US Patent for Improved Production of Synthetic Hypericin Composition
Oct 03, 2019
Soligenix to Present at the 20th Annual GCFF Investor Conference in Vancouver, British Columbia, Canada
Aug 13, 2019
Soligenix Announces Recent Accomplishments And Second Quarter 2019 Financial Results
Jul 08, 2019
Soligenix Announces Appointment of Diane L. Parks to its Board of Directors